Navigation Links
Sangui BioTech International, Inc. Files Remaining Reports
Date:9/8/2008

Shareholders' Meeting to be Held on October 9, 2008

WITTEN, Germany, September 8 /PRNewswire/ -- On Wednesday, August 27, 2008, Sangui BioTech International, Inc., filed with the SEC its financial statements on Form 10KSB for the 2007 financial year (ended June 30, 2007) as well as the quarterly reports on Forms 10QSB for the quarters ended September 30, 2007, December 31, 2007 as well as March 31, 2008. The company is now current with its SEC filings.

The Board of Directors has set the date for the forthcoming shareholders' meeting at October 9, 2007 at 11 a.m. Central European Time. It will take place in Witten, Germany. The preliminary agenda and proxy statement are available on the corporate website http://www.sanguibiotech.com. All documents as well as the date of the meeting are subject to SEC approval, Shareholders will be informed of any changes via the corporate website.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (http://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49-160-741-27-17

Fax: +49-2302-915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui Bio Tech International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangui Partnership Enters a New Phase:
2. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
3. Investors Acquire Share in Sangui BioTech GmbH
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):